← Back to list
MA08.174, Secukinumab (Cosentyx®) for Intravenous Use
Effective date
Not stated in the notice
Identified
Jun 19, 2026
Summary
Independence Blue Cross reissued MA08.174 on 05/27/2026 with no substantive changes to coverage criteria for secukinumab (Cosentyx) intravenous use. This is a routine policy reaffirmation communicating the company's continuing position on coverage for psoriatic arthritis, ankylosing spondylitis, and nonradiographic axial spondyloarthritis in Medicare Advantage members. No billing workflow changes are required.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01No immediate action required.
02This is a reissue with no changes to coverage criteria, medical necessity requirements, or billing codes.
03Billing team should note the 05/27/2026 reissue date for compliance records.
04Continue following existing prior authorization and documentation requirements for HCPCS code J3247 (secukinumab injection) when submitted for the specified diagnoses under Medicare Advantage plans.
Codes mentioned
J3247L40.50L40.51L40.52L40.53L40.59M45.0M45.1M45.2M45.3M45.4M45.5M45.6
Original notice
MA08.174, Secukinumab (Cosentyx®) for Intravenous Use
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.174, Secukinumab (Cosentyx®) for Intravenous UseLowNo effective date · Pharmacy08.02.28, Secukinumab (Cosentyx®) for Intravenous UseLowEffective Aug 26, 2024 · Pharmacy08.02.28, Secukinumab (Cosentyx®) for Intravenous UseLowEffective Aug 26, 2024 · PharmacyBrowse every Independence Blue Cross change in the policy list